Citations (54)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Angela Pirillo & Alberico L. Catapano. (2022) Evinacumab: a new option in the treatment of homozygous familial hypercholesterolemia. Expert Opinion on Biological Therapy 22:7, pages 813-820.
Read now
Read now
Yanli Gao, Baoqi Zhang & Junyi Yang. (2022) Evinacumab for the treatment of homozygous familial hypercholesterolemia. Expert Review of Clinical Pharmacology 15:2, pages 139-145.
Read now
Read now
Articles from other publishers (52)
Rai Ajit K. Srivastava. (2023) New opportunities in the management and treatment of refractory hypercholesterolemia using in vivo CRISPR-mediated genome/base editing. Nutrition, Metabolism and Cardiovascular Diseases 33:12, pages 2317-2325.
Crossref
Crossref
Blaine A. Pfeifer, Marie Beitelshees, Andrew Hill, Justin Bassett & Charles H. Jones. (2023) Harnessing synthetic biology for advancing RNA therapeutics and vaccine design. npj Systems Biology and Applications 9:1.
Crossref
Crossref
Peeyush Jain. (2023) Traditional and novel non-statin lipid-lowering drugs. Indian Heart Journal.
Crossref
Crossref
Joanna Rogozik, Renata Główczyńska & Marcin Grabowski. (2023) Genetic backgrounds and diagnosis of familial hypercholesterolemia. Clinical Genetics.
Crossref
Crossref
Elina Ikonen & Vesa M. Olkkonen. (2023) Intracellular Cholesterol Trafficking. Cold Spring Harbor Perspectives in Biology 15:8, pages a041404.
Crossref
Crossref
Daniel Tobias Michaeli, Julia Caroline Michaeli, Sebastian Albers, Tobias Boch & Thomas Michaeli. (2023) Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention. American Journal of Cardiovascular Drugs.
Crossref
Crossref
Ameet Sarpatwari, Beatrice L. Brown, Sarah A. McGraw, Sara Z. Dejene, Abdurrahman Abdurrob & Aaron S. Kesselheim. (2023) Physician experiences with and perceptions of risk evaluation and mitigation strategy programs with elements to assure safe use. PLOS ONE 18:7, pages e0288008.
Crossref
Crossref
Ting LUO, Chunxiao HUO, Tianhua ZHOU & Shanshan XIE. (2023) Progresses on RNA-based therapeutics for genetic diseases. Journal of Zhejiang University (Medical Sciences).
Crossref
Crossref
Rai Ajit K. Srivastava. (2023) A Review of Progress on Targeting LDL Receptor-Dependent and -Independent Pathways for the Treatment of Hypercholesterolemia, a Major Risk Factor of ASCVD. Cells 12:12, pages 1648.
Crossref
Crossref
Jonathan Hall. (2023) Future directions for medicinal chemistry in the field of oligonucleotide therapeutics. RNA 29:4, pages 423-433.
Crossref
Crossref
Joel Yong, Albert S. Mellick, John Whitelock, Joseph Wang & Kang Liang. (2023) A Biomolecular Toolbox for Precision Nanomotors. Advanced Materials, pages 2205746.
Crossref
Crossref
Yongguang Gao, Xinhua Liu, Na Chen, Xiaochun Yang & Fang Tang. (2023) Recent Advance of Liposome Nanoparticles for Nucleic Acid Therapy. Pharmaceutics 15:1, pages 178.
Crossref
Crossref
Rebecca Kohnken, Carole Harbison, Stephanie Klein & Jeffery A. Engelhardt. 2023. Haschek and Rousseaux's Handbook of Toxicologic Pathology, Volume 2 : Safety Assessment Environmental Toxicologic Pathology. Haschek and Rousseaux's Handbook of Toxicologic Pathology, Volume 2 : Safety Assessment Environmental Toxicologic Pathology
231
268
.
Dick C Chan, Jing Pang & Gerald F Watts. 2023. Lipoprotein(a). Lipoprotein(a)
91
111
.
Toufik Abdul-Rahman, Syed Muhammad Awais Bukhari, Emiliano Cantu Herrera, Wireko Andrew Awuah, Jannel Lawrence, Heloisa de Andrade, Neal Patel, Rohan Shah, Raheel Shaikh, Camilo Andrés Avendaño Capriles, Sebahat Ulusan, Shahzaib Ahmad, Anna Chiara Corriero, Adriana C. Mares, Akshay Goel, Adrija Hajra, Dhrubajyoti Bandyopadhyay & Rahul Gupta. (2022) Lipid Lowering Therapy: An Era Beyond Statins. Current Problems in Cardiology 47:12, pages 101342.
Crossref
Crossref
Mingqi Ouyang, Chenyu Li, Die Hu, Daoquan Peng & Bilian Yu. (2022) Mechanisms of unusual response to lipid-lowering therapy: PCSK9 inhibition. Clinica Chimica Acta.
Crossref
Crossref
Richa Saxena, Sana Ansari, Richa Sharma, Keshwanand Tripathi, Pankaj Kumar Rai, Naima Mirza, Mohd. Tahir, Anshdha Johari, Hemanreet Kaur, Aman Noor & Ashal Ilyas. 2022. Role of Microbes in Industrial Products and Processes. Role of Microbes in Industrial Products and Processes
35
58
.
Xiaoxin Li, Hongzhao Qi, Weigang Cui, Zhibin Wang, Xiuxiu Fu, Tianxiang Li, Huibo Ma, Yanyan Yang & Tao Yu. (2022) Recent advances in targeted delivery of non-coding RNA-based therapeutics for atherosclerosis. Molecular Therapy 30:10, pages 3118-3132.
Crossref
Crossref
Rahagir Salekeen, Abu Nasim Haider, Fouzia Akhter, Md Morsaline Billah, Md Emdadul Islam & Kazi Mohammed Didarul Islam. (2022) Lipid oxidation in pathophysiology of atherosclerosis: Current understanding and therapeutic strategies. International Journal of Cardiology Cardiovascular Risk and Prevention 14, pages 200143.
Crossref
Crossref
Mauro Sousa de Almeida, Barbara Rothen-Rutishauser, Michael Mayer & Maria Taskova. (2022) Multi-Functionalized Heteroduplex Antisense Oligonucleotides for Targeted Intracellular Delivery and Gene Silencing in HeLa Cells. Biomedicines 10:9, pages 2096.
Crossref
Crossref
Brendan P. Wilkins, Angela M. Finch, Yan Wang & Nicola J. Smith. (2022) Orphan GPR146: an alternative therapeutic pathway to achieve cholesterol homeostasis?. Trends in Endocrinology & Metabolism 33:7, pages 481-492.
Crossref
Crossref
Ruoyu Chen, Shaoyi Lin & Xiaomin Chen. (2022) The promising novel therapies for familial hypercholesterolemia. Journal of Clinical Laboratory Analysis 36:7.
Crossref
Crossref
David Curtis. (2022) Analysis of 200 000 exome-sequenced UK Biobank subjects illustrates the contribution of rare genetic variants to hyperlipidaemia. Journal of Medical Genetics 59:6, pages 597-604.
Crossref
Crossref
Julia M. Migliorati, Sunna Liu, Anna Liu, Anagha Gogate, Sreenidhi Nair, Raman Bahal, Theodore P. Rasmussen, José E. Manautou & Xiao-bo Zhong. (2022) Absorption, Distribution, Metabolism, and Excretion of US Food and Drug Administration–Approved Antisense Oligonucleotide Drugs. Drug Metabolism and Disposition 50:6, pages 888-897.
Crossref
Crossref
Antoine Gardin, Katharina Remih, Emmanuel Gonzales, Emma Rachel Andersson & Pavel Strnad. (2022) Modern therapeutic approaches to liver-related disorders. Journal of Hepatology 76:6, pages 1392-1409.
Crossref
Crossref
Giulio Bicciato, Markus Arnold, Aidan Gebhardt & Mira Katan. (2022) Precision medicine in secondary prevention of ischemic stroke: how may blood-based biomarkers help in clinical routine? An expert opinion. Current Opinion in Neurology 35:1, pages 45-54.
Crossref
Crossref
Karl Otfried Schwab & Jürgen DoerferKarl Otfried Schwab & Jürgen Doerfer. 2022. Pädiatrische Fettstoffwechselstörungen und Atheroskleroserisiko – kompakt. Pädiatrische Fettstoffwechselstörungen und Atheroskleroserisiko – kompakt
187
215
.
Pia Laitinen, Tiia A. Turunen & Mikko P. Turunen. 2022. Biotechnologies for Gene Therapy. Biotechnologies for Gene Therapy
45
59
.
Henry N Ginsberg, Chris J Packard, M John Chapman, Jan Borén, Carlos A Aguilar-Salinas, Maurizio Averna, Brian A Ference, Daniel Gaudet, Robert A Hegele, Sander Kersten, Gary F Lewis, Alice H Lichtenstein, Philippe Moulin, Børge G Nordestgaard, Alan T Remaley, Bart Staels, Erik S G Stroes, Marja-Riitta Taskinen, Lale S Tokgözoğlu, Anne Tybjaerg-Hansen, Jane K Stock & Alberico L Catapano. (2021) Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society. European Heart Journal 42:47, pages 4791-4806.
Crossref
Crossref
J. Víšek, M. Bláha, V. Bláha, M. Lášticová, M. Lánska, C. Andrýs, J. Duintjer Tebbens, Ivone Cristina Igreja e Sá, K. Tripská, M. Vicen, I. Najmanová & P. Nachtigal. (2021) Monitoring of up to 15 years effects of lipoprotein apheresis on lipids, biomarkers of inflammation, and soluble endoglin in familial hypercholesterolemia patients. Orphanet Journal of Rare Diseases 16:1.
Crossref
Crossref
Woan-Yuh Tarn, Yun Cheng, Shih-Han Ko & Li-Min Huang. (2021) Antisense Oligonucleotide-Based Therapy of Viral Infections. Pharmaceutics 13:12, pages 2015.
Crossref
Crossref
Taylor Gill, Haichuan Wang, Raj Bandaru, Matthew Lawlor, Chenyue Lu, Linda T. Nieman, Junyan Tao, Yixian Zhang, Daniel G. Anderson, David T. Ting, Xin Chen, James E. Bradner & Christopher J. Ott. (2021) Selective targeting of MYC mRNA by stabilized antisense oligonucleotides. Oncogene 40:47, pages 6527-6539.
Crossref
Crossref
Maciej Banach, Paweł Burchardt, Krzysztof Chlebus, Piotr Dobrowolski, Dariusz Dudek, Krzysztof Dyrbuś, Mariusz Gąsior, Piotr Jankowski, Jacek Jóźwiak, Longina Kłosiewicz-Latoszek, Irina Kowalska, Maciej Małecki, Aleksander Prejbisz, Michał Rakowski, Jacek Rysz, Bogdan Solnica, Dariusz Sitkiewicz, Grażyna Sygitowicz, Grażyna Sypniewska, Tomasz Tomasik, Adam Windak, Dorota Zozulińska-Ziółkiewicz & Barbara Cybulska. (2021) 2021 PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on the diagnosis and therapy of lipid disorders in Poland. Diagnostyka Laboratoryjna 57:1, pages 1-99.
Crossref
Crossref
Manish Pandey, Divya Ojha, Sakshi Bansal, Ambadas B. Rode & Geetanjali Chawla. (2021) From bench side to clinic: Potential and challenges of RNA vaccines and therapeutics in infectious diseases. Molecular Aspects of Medicine 81, pages 101003.
Crossref
Crossref
M Doortje Reijman, D Meeike Kusters & Albert Wiegman. (2021) Advances in familial hypercholesterolaemia in children. The Lancet Child & Adolescent Health 5:9, pages 652-661.
Crossref
Crossref
Hironori Adachi, Martin Hengesbach, Yi-Tao Yu & Pedro Morais. (2021) From Antisense RNA to RNA Modification: Therapeutic Potential of RNA-Based Technologies. Biomedicines 9:5, pages 550.
Crossref
Crossref
Zhili Tian, Guohui Liang, Kunli Cui, Yayu Liang, Qun Wang, Shuangyu Lv, Xiaoxia Cheng & Lei Zhang. (2021) Insight Into the Prospects for RNAi Therapy of Cancer. Frontiers in Pharmacology 12.
Crossref
Crossref
Xin Su, Ye Cheng & Dong Chang. (2021) Lipid-lowering therapy: Guidelines to precision medicine. Clinica Chimica Acta 514, pages 66-73.
Crossref
Crossref
Karen Duffy, Sebastian Arangundy-Franklin & Philipp Holliger. (2020) Modified nucleic acids: replication, evolution, and next-generation therapeutics. BMC Biology 18:1.
Crossref
Crossref
Hanna Ruhanen, P.A. Nidhina Haridas, Matti Jauhiainen & Vesa M. Olkkonen. (2020) Angiopoietin-like protein 3, an emerging cardiometabolic therapy target with systemic and cell-autonomous functions. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids 1865:12, pages 158791.
Crossref
Crossref
Melissa Wojtyniak, Boris Schmidtgall, Philine Kirsch & Christian Ducho. (2020) Towards Zwitterionic Oligonucleotides with Improved Properties: the NAA/LNA‐Gapmer Approach. ChemBioChem 21:22, pages 3234-3243.
Crossref
Crossref
Navin Kumar Verma, Mobashar Hussain Urf Turabe Fazil, Shane P. Duggan & Dermot Kelleher. (2020) Combination Therapy Using Inhalable GapmeR and Recombinant ACE2 for COVID-19. Frontiers in Molecular Biosciences 7.
Crossref
Crossref
Alexandre M. Bélanger, Leo Akioyamen, Latifah Alothman & Jacques Genest. (2020) Evidence for improved survival with treatment of homozygous familial hypercholesterolemia. Current Opinion in Lipidology 31:4, pages 176-181.
Crossref
Crossref
Irena Wieleba, Kamila Wojas-Krawczyk & Paweł Krawczyk. (2020) Aptamers in Non-Small Cell Lung Cancer Treatment. Molecules 25:14, pages 3138.
Crossref
Crossref
Raashda A Sulaiman. (2020) Inherited metabolic disorders and dyslipidaemia. Journal of Clinical Pathology 73:7, pages 384-390.
Crossref
Crossref
Cui-Cui Ma, Zhen-Ling Wang, Ting Xu, Zhi-Yao He & Yu-Quan Wei. (2020) The approved gene therapy drugs worldwide: from 1998 to 2019. Biotechnology Advances 40, pages 107502.
Crossref
Crossref
Tejal Aslesh & Toshifumi Yokota. 2020. Gapmers. Gapmers
69
85
.
Leanna Chan & Toshifumi Yokota. 2020. Gapmers. Gapmers
21
47
.
C. Macchi, C.R. Sirtori, A. Corsini, R.D. Santos, G.F. Watts & M. Ruscica. (2019) A new dawn for managing dyslipidemias: The era of rna-based therapies. Pharmacological Research 150, pages 104413.
Crossref
Crossref
Constance E. Cephus, Athar M. Qureshi, S. Kristen Sexson Tejtel, Mahboob Alam & Douglas S. Moodie. (2019) Coronary artery disease in a child with homozygous familial hypercholesterolemia: Regression after liver transplantation. Journal of Clinical Lipidology 13:6, pages 880-886.
Crossref
Crossref
Qinqin Pu, Ping Lin, Zhihan Wang, Pan Gao, Shugang Qin, Luqing Cui & Min Wu. (2019) Interaction among inflammasome, autophagy and non-coding RNAs: new horizons for drug. Precision Clinical Medicine 2:3, pages 166-182.
Crossref
Crossref
Federica Fogacci, Nicola Ferri, Peter P. Toth, Massimiliano Ruscica, Alberto Corsini & Arrigo F. G. Cicero. (2019) Efficacy and Safety of Mipomersen: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Drugs 79:7, pages 751-766.
Crossref
Crossref